HemoGenyx Pharmaceuticals Plc Statistics
Want to see GB:HEMO full AI Analyst Report?
HemoGenyx Pharmaceuticals Plc (HEMO) Stock Statistics & Valuation Metrics
Total Valuation
HemoGenyx Pharmaceuticals Plc has a market cap or net worth of GBX 46.90M. The enterprise value is GBX 45.81M.
- Market Cap
- GBX 46.90M
- Enterprise Value
- GBX 45.81M
Share Statistics
HemoGenyx Pharmaceuticals Plc has 6,896,786 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,896,786
- Owned by Insiders
- 11.83%
- Owned by Institutions
- ―
Financial Efficiency
HemoGenyx Pharmaceuticals Plc’s return on equity (ROE) is -8.16 and return on invested capital (ROIC) is -148.02%.
- Return on Equity (ROE)
- -8.16
- Return on Assets (ROA)
- -2.34
- Return on Invested Capital (ROIC)
- -148.02%
- Return on Capital Employed (ROCE)
- -1.72
- Revenue Per Employee
- 0
- Profits Per Employee
- -610.02K
- Employee Count
- 16
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of HemoGenyx Pharmaceuticals Plc is -3.76. HemoGenyx Pharmaceuticals Plc’s PEG ratio is -0.04.
- PE Ratio
- -3.76
- PS Ratio
- 0.00
- PB Ratio
- 10.13
- Price to FCF
- -35.55
- Price to Operating Cash Flow
- -33.22
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, HemoGenyx Pharmaceuticals Plc had revenue of 0 and earned -9.76M in profits. Earnings per share was -2.20.
- Revenue
- 0
- Gross Profit
- -588.75K
- Operating Income
- -4.66M
- Pretax Income
- -9.77M
- Net Income
- -9.76M
- EBITDA
- -4.07M
- Earnings Per Share (EPS)
- -2.20
Cash Flow
In the last 12 months, operating cash flow was -1.32M and capital expenditures -2, giving a free cash flow of -1.32M billion.
- Operating Cash Flow
- -1.32M
- Free Cash Flow
- -1.32M
- Free Cash Flow per Share
- -0.20
Dividends & Yields
HemoGenyx Pharmaceuticals Plc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.81%
- Earnings Yield
- -25.81%
Stock Price Statistics
- Beta
- -0.40
- 52-Week Price Change
- -24.61%
- 50-Day Moving Average
- 584.39
- 200-Day Moving Average
- 749.20
- Relative Strength Index (RSI)
- 55.90
- Average Volume (3m)
- 23.52K
Important Dates
HemoGenyx Pharmaceuticals Plc upcoming earnings date is Apr 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 28, 2026
- Next Earnings Date
- Apr 23, 2027
- Ex-Dividend Date
- ―
Financial Position
HemoGenyx Pharmaceuticals Plc as a current ratio of 1.38, with Debt / Equity ratio of 167.66%
- Current Ratio
- 1.38
- Quick Ratio
- 1.38
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.10
- Interest Coverage Ratio
- -20.30
Taxes
In the past 12 months, HemoGenyx Pharmaceuticals Plc has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
HemoGenyx Pharmaceuticals Plc EV to EBITDA ratio is -4.84, with an EV/FCF ratio of -33.48.
- EV to Sales
- 0.00
- EV to EBITDA
- -4.84
- EV to Free Cash Flow
- -33.48
- EV to Operating Cash Flow
- -33.48
Balance Sheet
HemoGenyx Pharmaceuticals Plc has GBX 4.58M in cash and marketable securities with GBX 1.85M in debt, giving a net cash position of GBX 2.73M billion.
- Cash & Marketable Securities
- GBX 4.58M
- Total Debt
- GBX 1.85M
- Net Cash
- GBX 2.73M
- Net Cash Per Share
- GBX 0.40
- Tangible Book Value Per Share
- GBX 0.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for HemoGenyx Pharmaceuticals Plc is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 18.57%
Scores
- Smart Score
- 1
- AI Score
- 49
